Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.
Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.
With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.
Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.
Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.
For the latest updates and further information, visit www.integralife.com.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported first quarter 2023 revenues of $380.8 million, marking a 1.1% increase year-over-year on a reported basis and 4.6% growth organically. GAAP earnings per diluted share were $0.29, down from $0.39 in the previous year, with adjusted earnings remaining steady at $0.74. The company reaffirmed its full-year revenue guidance of $1,602 to $1,620 million and adjusted EPS guidance of $3.43 to $3.51. Segment performance showed $248.1 million in revenues from Codman Specialty Surgical, while Tissue Technologies generated $132.7 million. Key highlights include strong demand across product lines and a successful launch of new products. The company also strengthened its balance sheet and returned value to shareholders through a $150 million share repurchase program.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will announce its first quarter 2023 financial results on April 26, 2023, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the earnings.
Investors can access the live webcast on the company's investor website. A replay of the call will be available afterward. Integra is renowned for its regenerative tissue technologies and neurosurgical solutions, providing high-quality products that support optimal patient care.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its 2022 financial results, revealing fourth quarter revenues of $398.0 million, a 1.8% decrease year-over-year, but a 2.9% organic growth. GAAP earnings per diluted share rose to $0.63 from $0.53 in Q4 2021. For the full year, revenues reached $1,557.7 million, a 1.0% increase, with GAAP EPS at $2.16. The company provided guidance for 2023, expecting revenues of $1,602 million to $1,620 million and adjusted EPS between $3.43 and $3.51, indicating optimism for growth as markets recover from COVID-19 impacts.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will announce its fourth quarter 2022 financial results on February 22, 2023, before the market opens. A conference call with the management team is scheduled for 8:30 a.m. ET on the same day. This event will be accessible via a live webcast on the company's investor website. Integra is recognized as a leader in regenerative tissue technologies and neurosurgical solutions, providing a wide range of high-quality products to enhance patient care. Investors can find further details and register for the call on their official site.
Campbell Soup Company (NYSE:CPB) announced the appointment of
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced preliminary financial results for the fourth quarter and full-year 2022, revealing expected revenues of $397-$398 million for Q4, a 2% decrease reported but a 3% organic increase year-over-year. For the full year, revenues are projected at $1,557-$1,558 million, reflecting a 1% reported increase and 4% organic growth. Adjusted earnings per diluted share for both periods are expected to exceed prior guidance. The company also plans a $150 million share repurchase program in 2023 and will present at the J.P. Morgan Healthcare Conference on January 11.
Integra LifeSciences (NASDAQ: IART) announced that its CEO, Jan De Witte, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 PM ET. A live webcast will be accessible through Integra's investor relations website. The company, recognized for its regenerative tissue technologies and neurosurgical solutions, aims to support clinicians in delivering optimal patient care. Integra boasts a robust portfolio of high-quality brands.
FAQ
What is the current stock price of Integra LifeSciences Holdings (IART)?
What is the market cap of Integra LifeSciences Holdings (IART)?
What does Integra LifeSciences Holdings Corp. specialize in?
Where is Integra LifeSciences headquartered?
What are the primary segments of Integra LifeSciences?
What recent acquisition was announced by Integra LifeSciences?
What are some of the key products offered by Integra LifeSciences?
How did Integra perform financially in the second quarter of 2023?
What is the purpose of Integra’s CereLink ICP Monitoring System?
How many employees does Integra LifeSciences have?
Which markets does Integra LifeSciences serve?
What is Integra’s strategy for growth in 2024?
